Previous close | 0.0400 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.5000 |
Strike | 3.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0400 - 0.0400 |
Contract range | N/A |
Volume | |
Open interest | 30 |
SAN DIEGO, May 03, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (T
Insiders who bought Gossamer Bio, Inc. ( NASDAQ:GOSS ) stock lover the last 12 months are probably not as affected by...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]